Mesoblast reports March quarter Ryoncil sales of $30.3M

Mesoblast (MESO) “announced Ryoncil net sales were $30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil launch approaches $100 million. Ryoncil revenue strengthens Mesoblast’s balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil(R) is the first mesenchymal stromal cell product approved by the U.S. Food and Drug Administration for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).”